EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of new prognostic molecular markers in glioblastoma: a single-center retrospective study

Adèle Meola iD, Bertille Segier iD, Aurore Siegfried iD, Amélie Lusque, Solène Evrard, Damien Pouessel, Delphine Dghayem, Franck-Emmanuel Roux iD, Sandra Soares, Maïlys Guillaumey, Ilfad Blazevic, Elizabeth Cohen-Jonathan Moyal iD und 1 weitere

The Oncologist · 10.04.2026 · 31 (5)

DOI: 10.1093/oncolo/oyag095 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 16.03.2026. Verfasst von Adèle Meola und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Univ Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole, Toulouse, 31059, France. Hauptthemen laut MEDLINE: Glioblastoma, Biomarkers, Tumor, Brain Neoplasms. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Glioblastoma (GBM) is the most common and aggressive primary CNS tumor in adults and carries a poor prognosis. Although molecular classification has advanced, patient outcomes remain variable. Next-generation sequencing (NGS) can reveal genomic alterations that, while not yet treatment-guiding, offer prognostic and biological insight. The study aimed to investigate the association between molecular alterations in primary GBM tumors and patient survival outcomes.

Methods

This study analyzed medical records of consecutive GBM patients treated between November 1, 2018 and December 31, 2021 at a comprehensive cancer center, for whom NGS data from the tumor was available. Survival analyses were performed according to clinical, radiological, therapeutic, and molecular data.

Results

Of 199 patients, 38 were excluded: 15 for recurrence-only data and 23 for incomplete molecular data after first progression. In the survival analysis of the cohort (n = 161) adjusted on surgical resection, MGMT promoter methylation status, number of alterations, age, tumor localization, MIB1 and performance status, EGFR substitutions were significantly associated with increased overall survival (OS) (HR = 0.43 [0.26; 0.72], P = .001), while CDKN2A/B loss and TP53 substitutions were associated with decreased OS (HR = 1.75 [1.08; 2.84], P = .023 and HR = 1.69 [1.04; 2.74], P = .034 respectively). NOTCH1 substitutions showed a trend towards improved progression-free survival (PFS) (HR = 0.55 [0.30; 1.01], P = .054).

Conclusion

We identified new prognostic markers in GBM, showing for the first time that EGFR substitutions improve OS. Validation in external cohorts and preclinical studies is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBiomarkers, TumorBrain NeoplasmsHumansPrognosisFemaleRetrospective StudiesMaleMiddle AgedAgedAdultErbB ReceptorsDNA Modification MethylasesTumor Suppressor ProteinsDNA Repair Enzymes

Stichwörter der Autor:innen

EGFRglioblastomamolecularprognostic factorsurvival analysis

Substanzen

Biomarkers, TumorErbB ReceptorsMGMT protein, humanDNA Modification MethylasesTumor Suppressor ProteinsDNA Repair Enzymes

Autor:innen und Institutionen

  • Department of Oncology, Univ Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole, Toulouse, 31059, France.
  • INSERM U1037, Cancer Research Center of Toulouse (CRCT), Toulouse, 31024, France.
  • Biostatistics and Health Data Science Unit, Univ Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole, Toulouse, 31059, France.
  • Department of Pathology, Univ Toulouse, Oncopole Claudius Regaud, IUCT-Oncopole, Toulouse, 31059, France.
  • Department of Neuroradiology, Hopital Pierre Paul Riquet, CHU Purpan, Toulouse, 31059, France.
  • Department of Neurosurgery, Hopital Pierre Paul Riquet, CHU Purpan, Toulouse, 31059, France.

ORCID-Profile: Adèle Meola, Bertille Segier, Aurore Siegfried, Franck-Emmanuel Roux, Elizabeth Cohen-Jonathan Moyal, Delphine Larrieu

Zitieren

APA

Meola, A., Segier, B., Siegfried, A., Lusque, A., Evrard, S., Pouessel, D., Dghayem, D., Roux, F. E., Soares, S., Guillaumey, M., Blazevic, I., Moyal, E. C., & Larrieu, D. (2026). Identification of new prognostic molecular markers in glioblastoma: a single-center retrospective study. The Oncologist, 31(5). https://doi.org/10.1093/oncolo/oyag095

Vancouver

Meola A, Segier B, Siegfried A, Lusque A, Evrard S, Pouessel D, et al. Identification of new prognostic molecular markers in glioblastoma: a single-center retrospective study. The Oncologist. 2026;31(5). doi:10.1093/oncolo/oyag095

BibTeX
@article{Meola2026,
  author = {Meola, Adèle and Segier, Bertille and Siegfried, Aurore and Lusque, Amélie and Evrard, Solène and Pouessel, Damien and Dghayem, Delphine and Roux, Franck-Emmanuel and Soares, Sandra and Guillaumey, Maïlys and Blazevic, Ilfad and Moyal, Elizabeth Cohen-Jonathan and Larrieu, Delphine},
  title = {Identification of new prognostic molecular markers in glioblastoma: a single-center retrospective study},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {5},
  doi = {10.1093/oncolo/oyag095}
}
Kostenlos starten →